Breast & Ovarian Cancer Predisposition Tests
Indications for Genetic Testing
- Family member diagnosed with breast cancer at age 45 or younger
- Triple negative breast cancer diagnosed in family
- Cancer in both breasts or Breast & ovarian cancers in the same family member
- Multiple breast cancers in the family or family history of Ovarian cancers
- Cases of male breast cancer in the family
- A family member with a BRCA1/2 gene mutation
- Two or more family members diagnosed with breast, ovarian, pancreatic or prostate cancer
GeneTech’s Breast and Ovarian cancer Gene panels
|S.No||Test name||TAT (Days)|
|1||BRCA1, BRCA2 or other genes targeted mutation detection||7|
|2||BRCA1 & BRCA2 Full Gene Sequencing||7|
|3||Breast & Ovarian Cancer Predisposition Gene Panel – 25 genes||7|
Sample Collection: 3ml Peripheral Blood in PURPLE TOP (EDTA) Vacutainer. Transport within 48 hrs at room temperature.
Known or Targeted mutation detection for Breast and Ovarian cancer predisposition:
Identifies risk for family members with known mutation information in the family
BRCA1 and BRCA2 Full gene sequencing:
Full gene sequencing of BRCA1 and BRCA2 tumor suppressor genes identifies thousands of mutations associated with risk pathology of breast and ovarian cancer.
Extended Breast and Ovarian Cancer predisposition Gene Panel:
Breast cancer susceptibility is associated with germline mutations in several genes. Our extended panel includes several genes other than BRCA1 and BRCA2 reported in asian population such as PTEN, TP53,PALB2, CDH1, STK11, ATM, BARD1, BRIP1, CDH1, CDKN2A, CHEK2, MLH1, MSH6, NF1, PALB2, PMS2, PTEN, RAD51C, and RAD51D.